Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Genta Suffers Another Setback With Bcl-2 Inhibitor Genasense

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Topline data from the firm’s Phase III study in treatment naive acute myelogenous leukemia patients fail to show survival benefit.

You may also be interested in...



Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.

Genta Genasense "Not Approvable"; Firm Blames Composite Endpoint

CEO Warrell tells "The Pink Sheet" DAILY that progression-free survival has no clinical value in the chronic lymphocytic leukemia setting.

Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007

Company continues to dispute FDA's position on clinical endpoints for relapsed/refractory CLL indication.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS063652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By